Rutgers Optimizes Innovation (ROI) Program

罗格斯大学优化创新 (ROI) 计划

• 批准号: 10316635
• 负责人: STEVEN K. LIBUTTI
• 金额: $ 44.36万
• 依托单位: RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-12-21 至 2023-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10316635
• 关键词: Academia; Address; Arts; Biocompatible Materials; Biomedical Engineering; Biomedical Research; Biomedical Technology; Businesses; Clinical; Collaborations; Conscious; Dental; Development; Discipline; Discipline of Nursing; Disease; Diverse Workforce; Engineering; Evaluation; Fostering; Funding; Future; Government; Health; Healthcare; Incubators; Industry; Infrastructure; Innovation Corps; Institutes; Laboratories; Lead; Leadership; Malignant Neoplasms; Mentors; Mission; Modeling; New Jersey; Pathogenesis; Pathway interactions; Patient Rights; Patients; Personal Satisfaction; Philosophy; Precision therapeutics; Probability; Process; Public Health; Public Health Schools; Research; Research Institute; Resources; School Nursing; Schools; Science; Societies; Solid; Technology; Therapeutic; Time; Training; Translating; Translational Research; Universities; Vision; base; care outcomes; commercialization; cost effective; design; diagnostic technologies; disease heterogeneity; education resources; improved; innovation; medical schools; member; next generation; population health; precision medicine; product development; programs; success; translational medicine; treatment response

Project Summary/Abstract The Rutgers Optimizes Innovation (ROI) Program will provide a vertically integrated mechanism to swiftly uncover promising biomedical product discoveries, and seamlessly guide the innovator through the commercialization process with financial and regulatory, IP protection, mentoring, management, and educational resources. Drawing on the biomedical/bioengineering sciences across Rutgers and on the solid expertise of the Office of Research Commercialization (ORC), we will integrate our strengths to uncover, develop and commercialize discoveries that improve health and well-being, and train the next generation of innovators. The ROI Program comprises a cooperative of Rutgers University and affiliates that includes the schools of engineering, arts and sciences, schools of medicine, nursing, dental science, public health, and research institutes and centers, industries, incubators, funders and policymakers. All entities provide significant resources to the ROI Program and have contributed to the planning, development, and leadership composition of the cooperative. Based in one of the most productive states with respect to commercialization of health-related discoveries (assets), the ROI Program will serve as a platform for translating biomedical discoveries into marketable products. Our REACH Hub will identify innovative health-related technologies by using the expertise of the NCI-funded Cancer Institute of NJ (CINJ), the Rutgers Institute for Translational Medicine and Science (RITMS, lead of the NCATS-funded CTSA) and the Biomaterials Center, funded by NSF and DOD. These technologies will be evaluated for commercialization feasibility, especially with respect to providing precision therapy to tackle an unmet need created by the heterogeneity of disease pathogenesis and response to treatment. Addressing such unmet needs will provide assets tailored to patients’ therapeutic responses that ultimately improves population health. The ROI Program will provide a streamlined and harmonized infrastructure that will enhance commercialization of academic discovery. The educational programs embedded in the ROI Program will provide our innovators with hands-on, practical training in product development and start-up requirements, while also training a diverse workforce in biomedical innovation by leveraging, coalescing and repurposing current resources, including I- Corps and iJOBS. Implementing a unique project management and mentoring program comprised of industry, disease-state and content experts will also enhance innovators’ opportunity for success. Embracing a Fail Fast Philosophy assures the technology will be developed in a cost-effective and market-conscious manner. Across all Aims, the ROI Program will collaborate with the REACH Consortium to build on their advances in platforms for commercialization, technology review, and training, and provide the Consortium with our expertise and commitment to serve as an active participating member. Importantly, evaluation milestones and metrics are planned in all aspects of the ROI Program to assure continuous quality assessment, improvement and sustainability.

项目摘要/摘要 Rutgers优化创新（ROI）计划将提供垂直集成的机制来迅速 发现承诺的生物医学产品发现，并通过 通过财务和监管，知识产权保护，心理，管理和教育的商业化流程 资源。利用跨罗格斯的生物医学/生物工程科学以及扎实的专业知识 研究商业化办公室（ORC），我们将整合我们的优势，以发现，发展和发展 商业化可以改善健康和福祉的发现，并培训下一代创新者。这 ROI计划包括罗格斯大学和分支机构的合作社，其中包括 工程，艺术和科学，医学院，护士，牙科科学，公共卫生和研究 研究所和中心，行业，孵化器，资金和决策者。 所有实体为ROI计划提供了重要的资源，并为计划，开发， 和合作社的领导力组成。基于最有生产力的国家之一 与健康相关发现的商业化（资产），ROI计划将作为翻译的平台 生物医学发现可销售的产品。我们的触及枢纽将确定与健康相关的创新 通过使用NCI资助的新泽西州NJ（CINJ）的专业知识，Rutgers研究所 转化医学与科学（RITMS，NCATS资助的CTSA的负责人）和生物材料中心， 由NSF和DOD资助。这些技术将用于商业化可行性，尤其是 尊重提供精确疗法以应对疾病异质性产生的未满足需求 发病机理和对治疗的反应。满足这种未满足的需求将为患者提供量身定制的资产 最终改善人口健康的治疗反应。 ROI计划将提供简化和统一的基础设施，以增强商业化 学术发现。 ROI计划中嵌入的教育计划将为我们的创新者提供 通过实践，实用的产品开发和启动要求培训，同时还培训潜水员 通过利用，合并和重新利用当前资源的生物医学创新劳动力，包括I- 军团和ijobs。实施独特的项目管理和心理计划完成了行业， 疾病状态和内容专家还将增强创新者成功的机会。快速拥抱失败 哲学假设该技术将以具有成本效益和市场意识的方式开发。穿过 所有目的，ROI计划将与Reach Consortium合作，以其在平台上的进步为基础 商业化，技术审查和培训，并为财团提供我们的专业知识和承诺 充当活跃的参与成员。重要的是，在各个方面都计划了评估里程碑和指标 ROI计划以确保持续的质量评估，改进和可持续性。